NEW YORK, May 13, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

The Boeing Company (NYSE: BA)
Class Period: January 8, 2019 - March 21, 2019
Lead Plaintiff Deadline: June 10, 2019
Join the action: https://www.zlk.com/pslra-1/the-boeing-company-loss-form-2?wire=3

About the lawsuit: The Boeing Company allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (1) Boeing’s 737 MAX airplanes were not as safe as previous models, therefore Boeing included undisclosed “hacks” created by engineering compromises and the lack of safety features which Boeing sold as “optional” add-ons which were designed to help address these safety concerns; (2) most airlines did not purchase these safety “options”; (3) the Federal Aviation Administration granted Boeing its own oversight and certification of Boeing’s new flight control system, or Maneuvering Characteristics Augmentation Systems, which was a clear conflict of interest as Boeing was rushing the 737 MAX airplanes to market; and (4) as a result of the foregoing, Boeing’s public statement were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To learn more about the The Boeing Company class action contact jlevi@levikorsinsky.com.

Indivior PLC (OTCMKTS: INVVY)
Class Period: March 10, 2015 - April 9, 2019
Lead Plaintiff Deadline: June 24, 2019
Join the action: https://www.zlk.com/pslra-1/indivior-plc-loss-form?wire=3

About the lawsuit: During the class period, Indivior PLC allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Indivior and its executives engaged in an illicit nationwide scheme to increase prescriptions of Suboxone Film; (2) Indivior illegally obtained billions of dollars in revenue from Suboxone Film prescriptions by deceiving health care providers and health care benefit programs; (3) as a result of the aforementioned misconduct, Indivior would face felony charges; and (4) due to the foregoing, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

To learn more about the Indivior PLC class action contact jlevi@levikorsinsky.com.

Sprint Corporation (NYSE: S)
Class Period: January 31, 2019 - April 16, 2019
Lead Plaintiff Deadline: June 21, 2019
Join the action: https://www.zlk.com/pslra-1/sprint-corporation-loss-form?wire=3

The complaint alleges that Sprint made materially false and misleading statements and/or failed to disclose material information. In particular, the complaint alleges that throughout the class period Sprint misrepresented the number of net postpaid subscriber additions in its Form 10-Q for the period ending December 31, 2018. Sprint would later admit that the data was “incomplete,” and “not a substitute for a realistic analysis of the key factors that are most probative of Sprint’s overall competitive position and prospects,” because “postpaid net additions recently have been driven by ‘free lines’ offered to Sprint customers and the inclusion of less valuable tablet and other non-phone devices, as well as pre to post migrations that do not represent ‘new’ Sprint customers.”

To learn more about the Sprint Corporation class action contact jlevi@levikorsinsky.com.

Boston Scientific Corporation (NYSE: BSX)
Class Period: February 26, 2015 - April 16, 2019
Lead Plaintiff Deadline: June 24, 2019
Join the action: https://www.zlk.com/pslra-1/boston-scientific-corporation-loss-form?wire=3

About the lawsuit: Boston Scientific Corporation allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (i) Boston Scientific’s surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse ("POP") were unsafe; (ii) accordingly, Boston Scientific’s continued marketing and sales of these devices in the United States was unlikely to be sustainable; (iii) separately, the Company had sold vaginal mesh implants containing counterfeit or adulterated resin products imported from China; (iv) the foregoing conduct subjected the Company to a heightened risk of regulatory scrutiny and/or government investigations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

To learn more about the Boston Scientific Corporation class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com